A carregar...
Administration of the Tablet Formulation of Olaparib in Patients with Ovarian Cancer: Practical Guidance and Expectations
Olaparib is a poly(ADP‐ribose) polymerase enzyme inhibitor that is approved for use in patients with advanced ovarian cancer (OC) and genetic BRCA1/2 mutations who have received three or more prior lines of chemotherapy for maintenance treatment of recurrent OC that is in response to platinum‐based...
Na minha lista:
| Publicado no: | Oncologist |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6067940/ https://ncbi.nlm.nih.gov/pubmed/29593098 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0485 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|